Long-Acting Risperidone Formulation for Schizophrenia Management

Clinical Guideline Support and Positioning

The American Psychiatric Association recommends considering the oral form of the same medication, such as risperidone, when initiating long-acting injectable treatment, confirming risperidone LAI availability 1, 2, 3
Current guidelines favor second-generation long-acting injectables like risperidone over first-generation agents due to better tolerability and fewer neurological side effects, according to the British Journal of Psychiatry 4, 5

Long-acting risperidone is indicated for patients with recurrent relapses related to non-adherence, patients with a history of frequent relapse on oral medication, and as first-line maintenance treatment after the first episode of schizophrenia, as per guidelines from the British Journal of Psychiatry 1, 2, 3
Patient preference for convenience is also a consideration for long-acting risperidone, as noted in the British Journal of Psychiatry 1, 2, 3